Antidepressive Agents, Second-Generation - Therapeutic use
Research News and Information

Sunday, November 22, 2009

Pharmacotherapy for depressed pregnant women: overcoming obstacles to gathering essential data.

29 Sep 2009 Approximately 3% of pregnant women take antidepressant medications. Information on the impact of antidepressants on short- and long-term maternal and offspring outcomes is highly desirable but neglected. The position that the dearth of treatment ... Read more...

[Pharmaceutical treatment of cancer-associated fatigue--a survey of a Cochrane review]

19 Sep 2009 The data and the conclusions of the Cochrane review of drug therapy for the management of cancer related fatigue (CRF) is analysed and summarized in this report. Overall, data is weakened substantially by a high degree of heterogeneity that stems ... Read more...

Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: a chart review.

30 Aug 2009 INTRODUCTION: There is no consensus regarding whether a previously prescribed, that is, failed, antidepressant should be continued or switched after a successful electroconvulsive therapy (ECT) for the maintenance of clinical remission in patients ... Read more...

Latest indexed articles for 'Antidepressive Agents, Second-Generation - Therapeutic use'

These are the very latest articles for this heading:

• Making the best use of available evidence: the case of new generation antidepressants: a response to: are all antidepressants equal? 30 Oct 2009
• Are all antidepressants equal? 30 Oct 2009
• Pharmacotherapy for depressed pregnant women: overcoming obstacles to gathering essential data. 29 Sep 2009
• Benefits exceed risks of newer antidepressant medications in youth--maybe not. 29 Sep 2009
• Benefits exceed risks of newer antidepressant medications in youth--maybe. 29 Sep 2009
• [Pharmaceutical treatment of cancer-associated fatigue--a survey of a Cochrane review] 19 Sep 2009
• Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: a chart review. 30 Aug 2009
• Antidepressant medication use during breastfeeding. 30 Aug 2009
• Restraint, hunger, and disinhibition following treatment for binge-eating disorder. 30 Aug 2009
• Bupropion-induced neck and shoulder pain. 30 Aug 2009
• Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. 30 Aug 2009
• Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. 30 Aug 2009
• Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. 24 Aug 2009
• Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial. 17 Aug 2009
• A comparison of several approaches for choosing between working correlation structures in generalized estimating equation analysis of longitudinal binary data. 13 Aug 2009
• Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. 9 Aug 2009
• Mean platelet volume in patients with major depression: effect of escitalopram treatment. 30 Jul 2009
• Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population. 30 Jun 2009
• Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. 29 Jun 2009
• Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. 29 Jun 2009

See a longer list of these articles.

Technical information about 'Antidepressive Agents, Second-Generation'

Definition: A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.

Registry Number: 0

Descriptor UI: D018687

Alternative terms: Antidepressive Agents, Second-Generation; Antidepressive Agents, Second Generation; Antidepressive Drugs, Second-Generation; Antidepressive Drugs, Second Generation; Drugs, Second-Generation Antidepressive; Second-Generation Antidepressive Drugs; Atypical Antidepressants; Second-Generation Antidepressive Agents; Agents, Second-Generation Antidepressive; Second Generation Antidepressive Agents; Antidepressants, Atypical;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.427.700.122.050;

History Note: 95

Technical Notes: GEN or unspecified; prefer specifics